Oct 30 / 2019
Latest News / Editorial/ Production

Cansativa obtains manufacturing and import authorisation in Germany

Cansativa is the only pharmaceutical company in the German medical cannabis market to have more than one GMP certified facility as an importer and wholesaler

The Frankfurt company Cansativa receives a manufacturing and an import license for medical cannabis after successful GMP approval inspections within the framework of the German Medicinal Products Act (Arzneimittelgesetz). This certification enables the import and marketing of medical cannabis products from all over the world via the two operating sites of the company headquartered in Frankfurt am Main. The pharmaceutical company will thus be able to control the major phases of the sales process in-house from its own distribution centers in the future.

The milestone expands the portfolio of suppliers to include companies from non-EU countries. Cansativa is already working closely with trusted partners from abroad to enable treatment with medical cannabis for as many seriously ill patients as possible. Instead of relying on a few individual manufacturers, Cansativa now strengthens its supply security with this broad global sourcing approach and considerably contributes to the professionalisation of the still young German medical cannabis market in the long term.

Benedikt Sons, CEO and Founder of Cansativa, emphasises: “Single sourcing of medical cannabis is not a sustainable model for us. The granting of manufacturing and import licenses is an important step towards security of supply. The manufacturing authorisation now enables us to release globally sourced products from our own production facilities.”

Added to this is the company’s broad positioning. Cansativa is the only company in the German medical cannabis market which is active both as an importer and a wholesaler and maintains two GMP certified operating sites at the same time.

“Commonly, people often talk about the existence of a large number of so-called importers in Germany. This is incomplete terminology. In terms of pharmaceutical law, an import in the actual sense always requires a batch release by a GMP-certified domestic manufacturer. In our market segment, there are very few companies besides Cansativa that can meet these requirements. Unlike most of our competitors, we are no longer just trading, we are manufacturing. This milestone allows us to move from being a wholesaler to a pharmaceutical company,” says Jakob Sons, General Counsel and Founder of Cansativa.

Cansativa is thus a pioneer in the industry and is constantly working to improve cannabis therapies. In addition, the company offers highly professional, integrated in-house solutions for relevant questions relating to medical cannabis, opening the market to new entrants.

About SiGMA:

The next SiGMA – World’s iGaming Village show is taking place in Malta between 27th and 29th November 2019.  Visit our website to reserve Delegate and Affiliate Passes. You can also choose Sponsorship and Exhibitor opportunities.

Share this entry: gplus-button facebook-button linkedin-button twitter-button
or go back to NEWS page